Unresectable/metastatic Small cell Lung Cancer (SCLC) research hub

Phase 1/2 multicenter, two-arms, open-label, dose-escalation study of IDP-121 in combination with chemotherapy in patients with relapsed small cell lung cancer (SCLC) (MYCrocytic)

This study is testing a new drug, IDP-121, combined with standard chemotherapy for people in the UK with a type of lung cancer called small cell lung cancer that has come back. It aims to find the right dose and see how well it works.